Cognition Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
CGTX Company Description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
CGTX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CGTX Smart Score
Score Breakdown
CGTX Company Description
Show More
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of CGTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CGTX's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of CGTX in WallStreetBets Daily Discussion
CGTX News
Recent insights relating to CGTX
CNBC Recommendations
Recent picks made for CGTX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CGTX
Corporate Flights
Flights by private jets registered to CGTX
Our Analysis